Exchange: NASDAQ·Updated 07:30 PM EST
NRIX logo

NRIX Nurix Therapeutics Inc

$12.85
$0.75
(5.51%)
Today
Closed $12.85
$0.00
(0.00%)
After Hours
EarningsJan 28
Mkt Cap$1.4B
Vol2.43M

About NRIX

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.
49

Neutral Sentiment

How do you feel about NRIX?

LabPsycho
$NRIX While the rational way to look at this is now NRIX is back to where it was before they got that 600M $. So, loss of potential $460M + $600M is net zero so back to where it was several months ago. But market is not rational and I think NRIX is Probably going below $15 because the market climate will use any excuse to sell a stock. Further I think this market fake rally today is a sucker rally - lots more pain ahead, not just for NRIX, the market and the country IMO. Good luck.
3
6
Lingus
$NRIX Huge overreaction. SAR448272 was a minor phase 1 trial. Bexobrutideg likely will be the major moneymaker.
1
3
Pika_Capital
$NRIX those morons who sold me shares on that day are going to be regretting big time in few years
1
2
MementoMori2023
$NRIX As right now, the market is taking almost 900 million of the market cap base on that news when prior to termination, Nurix was only eligible for an additional $453 million in future milestone payments specifically tied to the STAT6 program and that was only if they succeed wuth all milestones.
5
BiotechButterflies
$NRIX ... really... a Ph1 program scrapped cos of non-clinical reasons.. given the really gold is in the Bexobrutideg Global Collaboration with Roche...
4
Biotech_Pharma_Investor
$NRIX Does SNY news justify a 40% drop?? Seems silly. On the other hand was $27 price yesterday reasonable? NRIX getting interesting again down here.
4
MaxDanger
$NRIX Between the cash and data released to date on their CLL degrader program, a market cap of 1.8 billion is too cheap. We have ash coming up in a couple weeks, any positive data could send this to the moon. This is too cheap here, I’m in at around $16 and think this should be a $30+ stock with where they sit with current programs, data released so far and cash position. Exciting times.
3
oaksapollo
$NRIX This is ridiculous. You're telling me 40% of the value of this company was a phase 1 molecule that had been in the clinic for a month? It's absurd.
3
oaksapollo
$NRIX Could not agree more. Kymera is already WAY ahead with STAT6. Nurix was never going to be first to market. I added a bunch between $16-17. More bexo data is likely to hit tomorrow morning when ASH abstracts come out, so I strongly suspect they're just getting the bad news out of the way before the good news comes.
3
oaksapollo
$NRIX man I was up over 100%, now nearly back to my cost. I did trim quite extensively at $25-28 but wow, I did not see this coming. Roche has to be at least discussing an acquisition at this point right? I bet $30/share would be enough ($3.25B). They get $1B back immediately in cash, they save $1.6B in milestones, they get 100% of bexo revenue. I mean it ends up costing them almost nothing right?
2
CH_Expat
$NRIX Not once, but twice or thrice I was fighting with myself when you posted stuff like that, remember APGE at 36 me waiting for 34.
2
MaxDanger
$NRIX I suspect Sanofi is buying $KYMR and that’s the reason they abruptly cancelled their partnership with nrix.
2
mimiwor
$NRIX stuff they terminate today wasn't even their main pipeline... cut the milestone payments but they have decent cash ;;its runway until 2029. Look at their pipelines...
2
Biotech_Pharma_Investor
$NRIX $1.1 billion cash. Runway ti 2H 2029. And lost $1.2 billion in market valuation due to Sanofi dropping a ph1 asset (we dont even know why- bad asset? or strategic move by Sanofi?)
2
LongTrainRunning
$NRIX we learned nothing new about Sanofi/STAT6 from Sands at UBS conference. Nurix learned nothing else from Sanofi. They received no reports or clinical data. That's disappointing.
1
Mjust
$NRIX — Reviewing the recent filings, a few things caught my attention. Nurix reported approximately $1.1B in cash and marketable securities after receiving $700M upfront from Roche. However, Q3’s $549.8M net income was largely driven by one-time Roche licensing revenue, not recurring commercial product sales. On Nov. 3, Sanofi discontinued the Phase 1 SAR448272 program, eliminating potential future milestones and royalties from that program. The cash position is strong, but clinical execution and partner decisions remain important risks. I’ll be watching the Phase 3 progress, spending, and how the Roche partnership develops.
1
DataClown
$NRIX Short sellers got ahead of the crash two weeks early. Official short interest climbed from 17,657,588 shares on Sep 30 to 20,607,897 shares by Oct 15, a 16.7% increase, representing 25.90% of the float with a days-to-cover of 9.2. Trading volume that day was only 16.76 million shares, not even enough to absorb the total short position, which points to long capitulation rather than short covering. On another note: market cap stands at $1.74 billion, while enterprise value is just $760 million. That implies the market values its entire pipeline at roughly $7 per share. The company held $1.1 billion in cash as of August 31, enough to sustain operations into the second half of 2029.
1
PensionPulse
$NRIX OUCH! This got smoked today after Sanofi terminates STAT6 drug development program
1
LongTrainRunning
$NRIX we'll get our first look at ASH abstracts before the market opens tomorrow. Good luck longs!
1
shoc24
$NRIX is ranked #2 in healthcare quality with a score of 96. I used Stock Meadow's scoring model. Build your own model and backtest it if you don't agree with mine.

Advertisement|Remove ads.